Biomea Fusion, Inc. SEC filings BMEA
Biomea Fusion, Inc. has 290 filings in SEC EDGAR's recent list, going back to Jan 15, 2021. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 5, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 14, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Apr 27, 2026 | Jun 10, 2026 |
| DEF 14A | Proxy statement | Apr 28, 2025 | Jun 11, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 18, 2025 | Jun 11, 2025 |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 12, 2024 |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 14, 2023 |
| DEFA14A | Additional proxy material | Apr 29, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 22, 2022 |
Showing 7 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BMEA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Carlos, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1840439
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.